In the wake of rejection by the Guinea-Bissau Ministry of Public Health, Frederik Schaltz-Buchholzer – one of the study’s ...
Zymeworks entered into a global licensing and collaboration agreement with Roche for ZW209, a trispecific T-cell engager ...
Racura is pursuing one of cancer’s most elusive targets, pairing a distinctive MYC-inhibition approach with a data-first path ...
Gilead Sciences has agreed to acquire an oral IL-23R inhibitor program, led by HCXT-2001, from privately held PepStar ...
Earlier this week, Eli Lilly announced it broke ground on a large site in Houston, Texas. The location will be one of ten US ...
Molecular testing firm Qiagen has agreed to a $52.22-per-share all-cash acquisition by EQT Private Equity.
BioXconomy highlights leading Black innovators and leaders in the biotechnology industry.
METiS TechBio has teamed up with Lilly in a deal worth $1.1bn, pairing AI-driven lipid design with pharma expertise to ...
Nnenna Ohaka Nnenna Ohaka is a Partnering and Investment reporter at BioXconomy. Equipped with a degree in biomedical sciences from the University of Warwick, she currently reports on the latest in ...
Germany’s Merck has agreed to acquire London-based Silence Therapeutics in an all-cash deal, adding a late-stage rare blood ...
IQVIA and Veeva extend their partnership, expanding sponsor access to Veeva's clinical trial and data management technology.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results